XML 32 R15.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Warrants - Note 9 | 12 Months Ended
--- | ---
Dec. 31, 2017
Notes to Financial Statements |
Warrants - Note 9 | 9. WARRANTS During the second quarter of 2017, we received $906,000 from the exercise of warrants to purchase 460,000 shares of common stock, which warrants were issued in connection with earlier financing transactions. The outstanding warrants to purchase 2.0 million shares of our common stock that we sold in our March 2014 offering have an exercise price of $2.47 per share and expire on the fifth anniversary of the date of issuance. The following table summarizes activity with respect to our common stock warrants for the periods shown below (in thousands):
|  |  | Warrants to |  |  | Weighted-
|  |  | purchase |  |  | average
|  |  | common |  |  | exercise
|  |  | shares |  |  | price
Outstanding at January 1, 2015 |  |  | 6,526 |  | $ | 3.08
Granted: |  |  |  |  |  |
Exercise price less than intrinsic value |  |  | - |  |  | -
Exercise price greater than intrinsic value |  |  | - |  |  | -
Exercised |  |  | (1,487) |  |  | 2.19
Canceled/expired |  |  | - |  |  | -
Outstanding at December 31, 2015 |  |  | 5,039 |  |  | 3.34
Granted: |  |  |  |  |  |
Exercise price less than intrinsic value |  |  | - |  |  | -
Exercise price greater than intrinsic value |  |  | - |  |  | -
Exercised |  |  | - |  |  | -
Canceled/expired |  |  | (1,278) |  |  | 6.24
Outstanding at December 31, 2016 |  |  | 3,761 |  |  | 2.23
Granted: |  |  |  |  |  |
Exercise price less than intrinsic value |  |  | - |  |  | -
Exercise price greater than intrinsic value |  |  | - |  |  | -
Exercised |  |  | (460) |  |  | 1.97
Canceled/expired |  |  | (1,328) |  |  | 1.97
Outstanding at December 31, 2017 |  |  | 1,973 |  | $ | 2.47
Exercisable at December 31, 2017 |  |  | 1,973 |  | $ | 2.47
There were no common stock warrants issued in 2017, 2016 or 2015. The following table summarizes information about our common stock warrants outstanding and exercisable at December 31, 2017 (in thousands):
|  |  | Warrants outstanding |  |  | Warrants exercisable
|  |  |  |  |  | Weighted- |  |  |  |  |  |  |  |  |
|  |  |  |  |  | average |  |  | Weighted- |  |  |  |  |  | Weighted-
|  |  | Outstanding at |  |  | remaining |  |  | average |  |  | Exercisable at |  |  | average
|  |  | December 31, |  |  | contractual term |  |  | exercise |  |  | December 31, |  |  | exercise
Range of exercise prices |  |  | 2017 |  |  | (in years) |  |  | price |  |  | 2017 |  |  | price
$1.92 - $3.07 |  |  | 1,973 |  |  | 1.21 |  | $ | 2.47 |  |  | 1,973 |  | $ | 2.47
|  |  | 1,973 |  |  |  |  |  |  |  |  | 1,973 |  |  |

X
- References No definition available. + Details
Name: | MVIS_NotesToFinancialStatementsAbstract
Namespace Prefix: | MVIS_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for derivatives and fair value of assets and liabilities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -URI http://asc.fasb.org/topic&trid=2229140 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -URI http://asc.fasb.org/topic&trid=2155941 + Details
Name: | us-gaap_DerivativesAndFairValueTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration